The Patient-Reported Outcomes, Community Engagement, and Language (PRO-CEL) Core enhances the objectives of the Center's research programs by supporting the array of MSK investigators who wish to capture self-reported information from culturally diverse patients, caregivers, clinical staff, and community members. The faculty of the PRO-CEL Core are nationally recognized social, behavioral sciences, and community-engagement experts who provide technical assistance to all users throughout their various stages of research, including grant and protocol development, research study assistant and support staff training, and result dissemination. The PRO-CEL Core aims to 1) provide expert consultation with respect to selection, analysis, and interpretation of psychometrically sound patient-reported outcomes (PROs) or other self-report instruments for the capture of health-related quality of life (HRQoL), health behavior change, symptom control, treatment-related adverse events (AEs), and quality of care; 2) support qualitative interview, focus group, and other observational research methodology for generating new testable hypotheses, developing novel assessment tools, and establishing cultural and linguistic equivalency of PRO measures; 3) provide pre-review and feedback of peer-reviewed funding applications consistent with ?best practices? in psychosocial, behavioral, and community-engaged oncology research, including culturally and linguistically responsive research; 4) assist with the creation of online surveys for data capture; and 5) provide methodological support for clinical trial, behavioral, and population-based research that seeks to engage community or minority populations. The services provided by the PRO-CEL Core have supported the research of 105 MSK investigators in the past year, and during the past grant period, the work of this Core has contributed to 397 peer-reviewed publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084832
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Arvold, Nils D; Armstrong, Terri S; Warren, Katherine E et al. (2018) Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol 20:897-906
De, Brian; Cahlon, Oren; Sine, Kevin et al. (2018) Early Axial Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation. J Pediatr Hematol Oncol 40:574-579
Chang, Kevin K; Yoon, Changhwan; Yi, Brendan C et al. (2018) Platelet-derived growth factor receptor-? and -? promote cancer stem cell phenotypes in sarcomas. Oncogenesis 7:47
Dupnik, K M; Bean, J M; Lee, M H et al. (2018) Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. Int J Tuberc Lung Dis 22:950-958
Roberts, Sheryl; Andreou, Chrysafis; Choi, Crystal et al. (2018) Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chem Sci 9:5646-5657
Romanoff, Anya; Zabor, Emily C; Petruolo, Oriana et al. (2018) Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers? Cancer 124:4314-4321
Schaff, Lauren R; Grommes, Christian (2018) Updates on Primary Central Nervous System Lymphoma. Curr Oncol Rep 20:11
Suryawanshi, Hemant; Morozov, Pavel; Straus, Alexander et al. (2018) A single-cell survey of the human first-trimester placenta and decidua. Sci Adv 4:eaau4788
Pandit-Taskar, Neeta (2018) Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods. Semin Hematol 55:22-32
Kamboj, Mini; Cohen, Nina; Huang, Yao-Ting et al. (2018) Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant :

Showing the most recent 10 out of 8799 publications